Sun Pharmaceutical Industries has agreed to acquire U.S. drugmaker Organon & Co in an all-cash deal valued at approximately $11.75 billion, including debt. The agreement stipulates Sun Pharma will purchase all outstanding Organon shares for $14.00 per share. This acquisition will grant Sun Pharma full ownership of Organon, a company focused on women's health, biosimilars, and established medicines.